Black Diamond Therapeutics (BDTX) has an average investment rating of buy and price targets ranging from $10 to $53, according to analysts polled by...
Black Diamond Therapeutics (BDTX) will incorporate OpenEye Scientific's Orion molecular design platform into its mutation-allostery-pharmacology drug...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
|Number of Employees||N/A|
|Recent SEC Filing||11/29/20213|
|52 Week Range||$5.86 - 37.76|
|Market Capitalization||$217.4 M|
|Shares Outstanding||36.2 M|
|Industry||Biotechnology||Next Earnings Announcement||03/24/2022|
|Call Open Interest (1d)*|
|Put Open Interest (1d)*|
|Call Volume (1d)*|
|Put Volume (1d)*|
|Put Call Open Interest Ratio (1d)*|
|Put Call Volume Ratio (1d)*|
|* Data delayed by up to 15 minutes|
|Price / Earnings||N/A|
|Earnings per Share||-$3.38|
|Beta vs. S&P 500||N/A|
|Net Profit Margin||N/A|
|Return on Equity||-46.24%|